Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway

Overview of attention for article published in Frontiers in Pharmacology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 1 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

Article in European Journal of Pharmacology (August 2024)

The clinicopathological features and possible physiological mechanisms of only the EGFR-T790M primary mutation in patients with lung adenocarcinoma

Article in Pathology - Research and Practice (May 2024)

The clinicopathological features and possible physiological mechanisms of only EGFR-T790M primary mutation in lung adenocarcinoma patients

Preprint in Research Square (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.